JOP20250007A1 - دواء لخفض كوليسترول ldl بالدم - Google Patents
دواء لخفض كوليسترول ldl بالدمInfo
- Publication number
- JOP20250007A1 JOP20250007A1 JOJO/P/2025/0007A JOP20250007A JOP20250007A1 JO P20250007 A1 JOP20250007 A1 JO P20250007A1 JO P20250007 A JOP20250007 A JO P20250007A JO P20250007 A1 JOP20250007 A1 JO P20250007A1
- Authority
- JO
- Jordan
- Prior art keywords
- blood
- medication
- ldl cholesterol
- lower ldl
- ldl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022113930 | 2022-07-15 | ||
| PCT/JP2023/025980 WO2024014524A1 (ja) | 2022-07-15 | 2023-07-14 | 血中ldlコレステロール低下剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20250007A1 true JOP20250007A1 (ar) | 2025-01-13 |
Family
ID=89536850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2025/0007A JOP20250007A1 (ar) | 2022-07-15 | 2025-01-13 | دواء لخفض كوليسترول ldl بالدم |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20260014122A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4556006A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2024014524A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250034041A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119546300A (cg-RX-API-DMAC7.html) |
| JO (1) | JOP20250007A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202408500A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024014524A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20110009T1 (hr) | 2003-09-03 | 2011-03-31 | Kowa Co. | Spoj kojim se aktivira ppar i farmaceutski pripravak koji ga sadrži |
| TWI696462B (zh) * | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| PT3275438T (pt) * | 2016-07-29 | 2021-01-25 | Kowa Co | Métodos de prevenção de eventos cardiovasculares em populações dislipidémicas de risco residual |
| US11446282B2 (en) * | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
| CA3085951C (en) * | 2017-12-21 | 2022-10-11 | Kowa Company, Ltd. | Methods of treatment of hypertriglyceridemia |
| EP4346809B1 (en) * | 2021-05-27 | 2026-07-15 | Kowa Company, Ltd. | Pemafibrate for use in treating liver disease |
-
2023
- 2023-07-14 JP JP2024533757A patent/JPWO2024014524A1/ja active Pending
- 2023-07-14 US US18/880,136 patent/US20260014122A1/en active Pending
- 2023-07-14 WO PCT/JP2023/025980 patent/WO2024014524A1/ja not_active Ceased
- 2023-07-14 TW TW112126331A patent/TW202408500A/zh unknown
- 2023-07-14 CN CN202380054016.8A patent/CN119546300A/zh active Pending
- 2023-07-14 EP EP23839693.1A patent/EP4556006A4/en active Pending
- 2023-07-14 KR KR1020247043248A patent/KR20250034041A/ko active Pending
-
2025
- 2025-01-13 JO JOJO/P/2025/0007A patent/JOP20250007A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4556006A1 (en) | 2025-05-21 |
| KR20250034041A (ko) | 2025-03-10 |
| EP4556006A4 (en) | 2026-01-07 |
| CN119546300A (zh) | 2025-02-28 |
| JPWO2024014524A1 (cg-RX-API-DMAC7.html) | 2024-01-18 |
| TW202408500A (zh) | 2024-03-01 |
| US20260014122A1 (en) | 2026-01-15 |
| WO2024014524A1 (ja) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0410266D0 (en) | Treatment of apoptosis | |
| JP2017075183A5 (cg-RX-API-DMAC7.html) | ||
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| MX2010004508A (es) | Suministro de agentes activos. | |
| NO20073456L (no) | Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| BR112023021131A2 (pt) | Tratamento de tremor essencial | |
| US20190216886A1 (en) | Topical Compositions And Methods For Treating Wounds | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| JP2021502392A5 (cg-RX-API-DMAC7.html) | ||
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| WO2021022058A3 (en) | Antiarrhythmic formulation | |
| Kumar et al. | A review on pharmaceutical, pharmacological and chemical aspects of serratiopeptidase as anti-inflammatory agent | |
| MA58093B1 (fr) | Nouveaux analogues d'insuline et leurs utilisations | |
| ATE481094T1 (de) | Behandlung von diabetischer nephropathie | |
| MX2025000682A (es) | Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma | |
| MA58327B2 (fr) | Nouveau composé de [2-(diméthylamino)-2-phénylbutyl]-3,4,5-triméthoxybenzoate 4-méthyl-2н-chromen-2-one-7-ylsulfate et son utilisation | |
| BR112023023702A2 (pt) | Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga | |
| Turlaev et al. | The role of society and economy in advancing hirudotherapy in Russia | |
| IL320111A (en) | Cnp compounds | |
| JP2024532129A5 (cg-RX-API-DMAC7.html) | ||
| BR112014001503A2 (pt) | composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele | |
| PH12023553231A1 (en) | Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| BR112022025900A2 (pt) | Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina | |
| RU2609017C1 (ru) | Способ лечения грибковых заболеваний ногтей |